Skip to main content

Closed

TCRX: TScan Therapeutics, Inc. Stock Analysis | finqOS

Healthcare · Biotechnology

Loading chart data...

Current StateBalance holding

The verdict

Good business

Weak

Revenue growth-86.6% / yr

Operating margin-1408.7%

ROIC-67.9%

Financially safe

Stretched

Debt / equity0.95×

Interest coverage-46.3×

Current ratio6.65×

TScan Therapeutics, Inc.

TCRXNASDAQ·USD·Closed

TScan Therapeutics, Inc.

TCRXNASDAQ·USD·Closed

$0.74

−1.68%

$0.74

−$0.01 (1.68%)

52W Range

1thpctl

Volume

0.35×avg

Mkt Cap

45.38MUSD

P/E

-0.8TTM

Div Yield

–ann

52W Range

1thpctl

Volume

0.35×avg

Market Cap

45.38MUSD

P/E Ratio

-0.8TTM

Div Yield

-ann

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings